FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3148674612> ?p ?o ?g. }

• W3148674612 endingPage "950" @default.
• W3148674612 startingPage "947" @default.
• W3148674612 abstract "Acute attacks could occur during the convalescent phase of COVID-19 illness, more commonly in patients with a history of frequent attacks. However it is unclear whether the acute attacks during the convalescent phase are specifically triggered by COVID-19 or not. Blockage of angiotensin-converting enzyme (ACE), an important enzyme degrading bradykinin into its metabolites, is known to play a key role in bradykinin-mediated angioedema.1 SARS-CoV-2 has been shown to enter human cell via ACE2 during COVID-19.2 The SARS-CoV-2 and ACE2 binding supposedly down-regulates ACE, thus interfering with bradykinin degradation and bradykinin concentration in extracellular space.3, 4 Therefore, we have concerns about showing the possibility of down-regulated ACE2 activity during COVID-19 resulting in bradykinin-mediated angioedema attacks in patient with hereditary angioedema (HAE). HAE is a rare, life-threatening, genetic disease5 characterized by transitory recurrent subcutaneous and/or submucosal swelling episodes which mainly affect skin, gastrointestinal tract, and upper airways.6 It should be divided in three forms according to the level of C1 inhibitor: HAE type I (HAE I) or II (HAE II) with C1-inhibitor deficiency (HAE C1-INH),6 and HAE with normal C1 inhibitor (HAE nC1-INH) level.7 In all forms, the swelling episodes are explained by a sudden, localized, and bradykinin-mediated increase of vascular permeability. Some triggers have been identified such as infection.8 We proposed to study the impact of the COVID-19 disease on HAE attacks. The National Angioedema Reference Centre (CREAK) created the AE-COVID-19 registry in order to collect data on the HAE COVID-19 impact in France (approved by the CNIL (the French commission for informatics and freedom) and the Ethics Committee (ref: MR1316170420). It aims to enrol all HAE patients who presented an acute COVID-19 infection. A case of COVID-19 was defined as positive serum anti-SARS-CoV-2 IgG antibodies (Wantai total antibody ELISA or Roche Elecsys total antibody assay) or as positive nasopharyngeal SARS-CoV-2 RNA (Abbott Alinity or Roche Cobas SARS-CoV-2 tests) associated with compatible COVID-19 symptoms (cough, dyspnoea, fever, myalgia, or arthralgia, anosmia, ageusia, fatigue, abdominal pain, and headache).9 Thanks to this registry, we could analyse prospectively data from 13 HAE patients including in 4 different centres between April 2020 and January 2021. Oral consent from all patient was collected. Continuous variables were compared using the non-parametric Mann-Whitney test. Categorical variables were compared using the Chi-square test (if number of patients was >5 patients) or using the McNemar Test. All tests were two-sided. The majority of patients were women (8/13) with a median age of 37 (range: 26–85). Two patients had a previous history of high blood pressure, one of diabetes and two of obesity. Clinical and biological characteristics of the patients are presented in Table 1. Ten were diagnosed with HAE I, 1 with type HAE II, and 2 with HAE nC1-INH (one with plasminogen mutation and one with factor XII deficiency). The last attack occurred with a median time of 80 days before COVID-19 (range interval: 8–1753). Six patients received prophylactic therapy (Danazol [3], Lanadelumab [3]). SARS-CoV-2 infection was symptomatic for all patients: asthenia (6), cough (8), dyspnoea (5), ageusia (9), anosmia (9), headache (5), and abdominal symptoms (3). The two oldest patients (85 and 65 years old) presented severe hypoxemic respiratory failure secondary to SARS-CoV-2 requiring oxygen therapy. The younger one was treated with mechanical ventilation after orotracheal intubation. They both recovered after 60 and 18 days of hospitalization respectively. They did not receive systematic HAE on-demand therapy after SARS-CoV-2 infection diagnostic to prevent attack. Four of thirteen patients developed HAE attacks during COVID-19 convalescence (median time between first symptoms and the end of follow-up: 90 days, range 8–193) (Table 2). These patients presented a lower HAE disease control than the other patients (median number of attacks per month 14 (range: 4–36) and 2 (range: 0.2–12) respectively, p = .02). All developed iterative moderate attacks based on visual analogue scale (VAS) (median attack number: 2.5, range: 2–5) during the convalescence. They described attacks affecting the face (1), abdominal area (3), and extremities (4). All patients were treated with on demand therapy: three of them received Icatibant, a B2 receptor antagonist which was recently tested for patient with COVID-19.4 The median duration was 37.5 hours (with broad range: 3–96). Patients with AE attacks during COVID (4) Patients without (9) Cough, dyspnoea ageusia, anosmia abdominal symptoms Cough, dyspnoea ageusia, anosmia respiratory distress In summary, in our cohort, only 31% of HAE patients developed attacks during SARS-CoV-2 infection. These results are in line with those of Grumach et al.10 Indeed, in their cohort of 13 patients, 5 (38%) experienced attacks days after SARS-CoV-2 infection, mostly affected extremities and face. Acute attacks could occur during the convalescent phase of COVID-19 illness, more commonly in patients with a history of frequent attacks. However, it is unclear whether the acute attacks during the convalescent phase are specifically triggered by COVID-19 or not. This current study has, however, several limitations among them, the small sample size. Nonetheless, it adds to the evidence that patients with a good HAE disease control are at low risk of developing angioedema attacks. This study is supported by French Reference Center for Angioedema, CREAK, and by research grants CNRS (GREPI/AGIM CNRS FRE 3405). No financial or material support exists. The authors thank Kenz Le Gouge. All authors report no disclosures. We certify that the submission is not under review at any other publication. The principal author, Laurence Bouillet, takes full responsibility for the data, the analyses and interpretation, and conduct of the research. Bouillet has full access to all data and has the right to publish any and/or all data, separately from or with any sponsor. No financial or other relationships exist that might lead to a perceived conflict of interest. Aude Belbezier contributed to acquisition of data, analysis, interpretation of the data, drafting the manuscript for intellectual contents, and final approval of the version to be published. Mélanie Arnaud and Chloé McAvoy contributed to acquisition of data and final approval of the version to be published. Isabelle Boccon-Gibod, Fabien Pelletier, Delphine Gobert, Olivier Fain, Aurélie Du-Thanh, David Launay, and Julien Lupo contributed to acquisition of data, critical revision of manuscript for intellectual content, and final approval of the version to be published. Laurence Bouillet contributed to study concept and design of the study, critical revision of manuscript for intellectual content, study supervision, and final approval of the version to be published. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions." @default.
• W3148674612 created "2021-04-13" @default.
• W3148674612 creator A5002922004 @default.
• W3148674612 creator A5005201501 @default.
• W3148674612 creator A5014020914 @default.
• W3148674612 creator A5041077575 @default.
• W3148674612 creator A5045287052 @default.
• W3148674612 creator A5046988752 @default.
• W3148674612 creator A5051293408 @default.
• W3148674612 creator A5066356763 @default.
• W3148674612 creator A5066689719 @default.
• W3148674612 creator A5080203920 @default.
• W3148674612 creator A5081908425 @default.
• W3148674612 date "2021-04-04" @default.
• W3148674612 modified "2023-10-10" @default.
• W3148674612 title "COVID‐19 as a trigger of acute attacks in people with hereditary angioedema" @default.
• W3148674612 cites W1983734540 @default.
• W3148674612 cites W2081368903 @default.
• W3148674612 cites W2170807355 @default.
• W3148674612 cites W2316464345 @default.
• W3148674612 cites W2567532594 @default.
• W3148674612 cites W3009912996 @default.
• W3148674612 cites W3010126769 @default.
• W3148674612 cites W3023519397 @default.
• W3148674612 cites W3108747739 @default.
• W3148674612 doi "https://doi.org/10.1111/cea.13870" @default.
• W3148674612 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8250827" @default.
• W3148674612 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33772888" @default.
• W3148674612 hasPublicationYear "2021" @default.
• W3148674612 type Work @default.
• W3148674612 sameAs 3148674612 @default.
• W3148674612 citedByCount "9" @default.
• W3148674612 countsByYear W31486746122021 @default.
• W3148674612 countsByYear W31486746122022 @default.
• W3148674612 countsByYear W31486746122023 @default.
• W3148674612 crossrefType "journal-article" @default.
• W3148674612 hasAuthorship W3148674612A5002922004 @default.
• W3148674612 hasAuthorship W3148674612A5005201501 @default.
• W3148674612 hasAuthorship W3148674612A5014020914 @default.
• W3148674612 hasAuthorship W3148674612A5041077575 @default.
• W3148674612 hasAuthorship W3148674612A5045287052 @default.
• W3148674612 hasAuthorship W3148674612A5046988752 @default.
• W3148674612 hasAuthorship W3148674612A5051293408 @default.
• W3148674612 hasAuthorship W3148674612A5066356763 @default.
• W3148674612 hasAuthorship W3148674612A5066689719 @default.
• W3148674612 hasAuthorship W3148674612A5080203920 @default.
• W3148674612 hasAuthorship W3148674612A5081908425 @default.
• W3148674612 hasBestOaLocation W31486746121 @default.
• W3148674612 hasConcept C116675565 @default.
• W3148674612 hasConcept C126322002 @default.
• W3148674612 hasConcept C159047783 @default.
• W3148674612 hasConcept C16005928 @default.
• W3148674612 hasConcept C177713679 @default.
• W3148674612 hasConcept C203014093 @default.
• W3148674612 hasConcept C2777788586 @default.
• W3148674612 hasConcept C2777995640 @default.
• W3148674612 hasConcept C2778137277 @default.
• W3148674612 hasConcept C2779134260 @default.
• W3148674612 hasConcept C3006700255 @default.
• W3148674612 hasConcept C3007834351 @default.
• W3148674612 hasConcept C3008058167 @default.
• W3148674612 hasConcept C524204448 @default.
• W3148674612 hasConcept C71924100 @default.
• W3148674612 hasConcept C89623803 @default.
• W3148674612 hasConceptScore W3148674612C116675565 @default.
• W3148674612 hasConceptScore W3148674612C126322002 @default.
• W3148674612 hasConceptScore W3148674612C159047783 @default.
• W3148674612 hasConceptScore W3148674612C16005928 @default.
• W3148674612 hasConceptScore W3148674612C177713679 @default.
• W3148674612 hasConceptScore W3148674612C203014093 @default.
• W3148674612 hasConceptScore W3148674612C2777788586 @default.
• W3148674612 hasConceptScore W3148674612C2777995640 @default.
• W3148674612 hasConceptScore W3148674612C2778137277 @default.
• W3148674612 hasConceptScore W3148674612C2779134260 @default.
• W3148674612 hasConceptScore W3148674612C3006700255 @default.
• W3148674612 hasConceptScore W3148674612C3007834351 @default.
• W3148674612 hasConceptScore W3148674612C3008058167 @default.
• W3148674612 hasConceptScore W3148674612C524204448 @default.
• W3148674612 hasConceptScore W3148674612C71924100 @default.
• W3148674612 hasConceptScore W3148674612C89623803 @default.
• W3148674612 hasIssue "7" @default.
• W3148674612 hasLocation W31486746121 @default.
• W3148674612 hasLocation W31486746122 @default.
• W3148674612 hasLocation W31486746123 @default.
• W3148674612 hasOpenAccess W3148674612 @default.
• W3148674612 hasPrimaryLocation W31486746121 @default.
• W3148674612 hasRelatedWork W3003901880 @default.
• W3148674612 hasRelatedWork W3005417802 @default.
• W3148674612 hasRelatedWork W3007868867 @default.
• W3148674612 hasRelatedWork W3009669391 @default.
• W3148674612 hasRelatedWork W3020699490 @default.
• W3148674612 hasRelatedWork W3043486364 @default.
• W3148674612 hasRelatedWork W3087206508 @default.
• W3148674612 hasRelatedWork W4206419631 @default.
• W3148674612 hasRelatedWork W4380742785 @default.
• W3148674612 hasRelatedWork W3127156785 @default.
• W3148674612 hasVolume "51" @default.
• W3148674612 isParatext "false" @default.

• next